Emergent BioSolutions announces approval from FDA for CYFENDUS vaccine
Earlier known as AV7909, CYFENDUS vaccine’s efficacy for post-exposure prophylaxis is only based on studies in animal models of inhalational anthrax. Emergent senior vice president, science and development